FILTER
FILTERED INTERVIEW RESULTS
Andrea Confetti and Roberto Fanelli
EXCLUSIVE SYNTHESIS BU LEADER (AC) & CATALOGUE APIS BU LEADER (RF), DIPHARMA FRANCIS
"Small molecule drugs dominate pharmaceutical development, holding almost 60% of the market in 2024, and FDA approvals for small molecules are expected to stay strong."
Donna LaVoie
FOUNDER AND CEO, LAVOIEHEALTHSCIENCE
"For biotechs, finding the balance between appealing to the public and institutional investors will be a challenge, much like trying to balance a recipe with the right mix of ingredients for the perfect dish."
Debbie Hart
PRESIDENT AND CEO, BIONJ
"New Jersey is home to eight of the top 10 global biopharmaceutical companies, nine of the top 10 R&D firms, and over 5,600 life sciences establishments. The State accounted for 43% of all novel FDA approvals in the past two years."
David Short
SR. MANAGER, BUSINESS DEVELOPMENT - US & CANADA, PROCOS S.P.A.
"Procos is poised for transformative growth in 2025. Our R11 facility will significantly enhance our small-scale production capacity, enabling us to meet the growing demand for high-quality, specialized APIs in the US market."
Arda Ural
PHD LIFE SCIENCES SECTOR LEADER, EY
"Heading to 2025, the outlook seems positive, particularly with US$1.3 trillion of capital available for dealmaking. This positions the industry to pursue external growth aggressively if internal pipelines fall short."
Gil Roth
PRESIDENT, PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION (PBOA)
"Early-stage R&D projects face longer timelines, making them less attractive when inflation remains high. If interest rates continue to decline, there could be increased investment in earlier-stage assets."
Gaurav Kaushik
MD AND CEO, METEORIC BIOPHARMACEUTICALS
"We have witnessed growing interest in utilizing plant-derived enzymes across various applications."
Saurabh Gurnurkar
MANAGING DIRECTOR, UQUIFA GROUP
"We can now initiate projects in Budapest and conclude them at our larger-scale GMP facility in Spain and/or Mexico, offering to our customers an option for integrated project management for their programs."
Tom Sellig
CEO, ADARE PHARMA SOLUTIONS
"There are hundreds of firms out there offering very specific services, and this will ultimately lead to more consolidation within the industry."
Victor Swint
CEO, FORMULATED SOLUTIONS
"Rather than merely facilitating tech transfers, we aspire to lead the innovation charge for our clients."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
